Lecanemab for Early Onset Familial Alzheimer's Disease

This study is testing lecanemab — a drug that targets abnormal amyloid protein buildup in the brain — in people with early-onset familial Alzheimer's disease (where symptoms appear at age 65 or younger, often due to a genetic predisposition). **You may be eligible if...** - You are between 18 and 65 years old - You have been diagnosed with mild cognitive impairment or mild Alzheimer's disease - Your diagnosis has been confirmed by brain imaging or spinal fluid testing showing amyloid buildup - You score within a certain range on standard memory tests (MMSE or MoCA) - You and your legal guardian can give informed consent **You may NOT be eligible if...** - Your memory problems are caused by something other than Alzheimer's (e.g., stroke, Parkinson's, vitamin deficiency, infection) - You have had a stroke, bleeding disorder, or seizures in the past 12 months - You have serious heart, lung, liver, kidney, or blood conditions - You are on blood thinners (warfarin, heparin, or similar drugs) - You are unable to undergo MRI scans - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.